Barclays’s Arcturus Therapeutics ARCT Stock Holding History

Barclays’s Portfolio ARCT Stock Details ARCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-68,500	Closed	-$1.26M	–	5225
2025 Q3	$1.26M	Buy	+68,500	New	+$1.1M	﹤0.01%	3227
2024 Q4	–	Sell	-45,000	Closed	-$1.04M	–	5257
2024 Q3	$1.04M	Sell	45,000 -105,000	-70%	-$2.25M	﹤0.01%	3327
2024 Q2	$3.65M	Buy	+150,000	New	+$4.55M	﹤0.01%	1730
2014 Q4	–	Sell	-54,457	Closed	-$5.72M	–	7247
2014 Q3	$5.72M	Buy	+54,457	New	+$7.1M	0.01%	1650

Other funds holding ARCT

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Barclays's ARCT Position: Q2 2026 in Review

Barclays increased its Arcturus Therapeutics (ARCT) stake by 1.1% in Q2 2026, buying an estimated $1.14K and bringing the position to 13,775 shares worth $92.6K. The position accounts for ﹤0.01% of the portfolio, ranked #4070.

Barclays first reported a position in ARCT in Q3 2014 and has held it in 41 quarters since. The position peaked at $3.29M in Q4 2020. 135 funds tracked by Wall St. Rank hold ARCT as of Q2 2026.

Barclays held 13,775 shares of Arcturus Therapeutics worth $92.6K as of Q2 2026.
Barclays bought 145 Arcturus Therapeutics shares in Q2 2026, an estimated $1.14K.
Arcturus Therapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #4070 holding.
Barclays first reported a position in Arcturus Therapeutics in Q3 2014 and has held it in 41 quarters since.
Barclays's Arcturus Therapeutics position peaked at $3.29M in Q4 2020.
135 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.